Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point ...

Shares of Danish biotech Genmab fell as much as 5% on Friday, after is released disappointing top-line clinical results for ...

While rare, secondary cancers after CAR T-cell therapy have been reported, leading the FDA to mandate boxed warnings on all approved therapies. In a first, targeted therapy was used to treat a T-cell ...

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...